GSK

1,858.5

-0.83%↓

GSK

1,858.5

-0.83%↓

GSK

1,858.5

-0.83%↓

GSK

1,858.5

-0.83%↓

GSK

1,858.5

-0.83%↓

Search

AstraZeneca PLC

Închisă

SectorSănătate

13,514 -3.07

Rezumat

Modificarea prețului

24h

Curent

Minim

13514

Maxim

13632

Indicatori cheie

By Trading Economics

Venit

1.6B

3.9B

Vânzări

-215M

15B

P/E

Medie Sector

27.389

51.415

EPS

1.29

Randament dividend

1.75

Marjă de profit

25.602

Angajați

96,100

EBITDA

1.1B

5.7B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+17.01% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

1.75%

2.34%

Următoarele câștiguri

27 iul. 2026

Următoarea dată ex-dividende

6 aug. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-8.7B

282B

Deschiderea anterioară

13517.07

Închiderea anterioară

13514

Sentimentul știrilor

By Acuity

26%

74%

53 / 345 Clasament în Healthcare

AstraZeneca PLC Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 apr. 2026, 16:28 UTC

Câștiguri

Correction to AstraZeneca Update

29 apr. 2026, 15:11 UTC

Câștiguri

AstraZeneca Plans U.K. Investment as Cancer Drugs Lift Revenue -- Update

29 apr. 2026, 06:31 UTC

Câștiguri

AstraZeneca Gets Revenue Boost From Cancer Drugs

27 mar. 2026, 10:04 UTC

Evenimente importante

Oil Climbs Higher, Stock Recovery Fades as Doubts Cloud Cease-Fire Hopes

13 mai 2026, 12:29 UTC

Market Talk

AstraZeneca Has Room to Grow in Heart Disease With Wainua -- Market Talk

13 mai 2026, 11:54 UTC

Market Talk

AstraZeneca Has Credible Growth Path Beyond 2030 -- Market Talk

1 mai 2026, 09:31 UTC

Market Talk

AstraZeneca Can Deal With Hit From FDA Cancer Drug Knockback -- Market Talk

29 apr. 2026, 10:29 UTC

Market Talk
Câștiguri

AstraZeneca Beats Expectations, But Focus Is on Busy Pipeline Ahead -- Market Talk

29 apr. 2026, 10:06 UTC

Market Talk
Câștiguri

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

29 apr. 2026, 09:53 UTC

Market Talk
Câștiguri

AstraZeneca Seems in Fine Health -- Market Talk

29 apr. 2026, 06:05 UTC

Câștiguri

AstraZeneca Says It Remains on Track to Achieve Ambition for 2030, Beyond

29 apr. 2026, 06:04 UTC

Câștiguri

AstraZeneca 1Q Ultomiris Revenue $1.27B, Up 18% at Constant Currency

29 apr. 2026, 06:04 UTC

Câștiguri

AstraZeneca 1Q Farxiga Revenue $2.19B, Down 2% at Constant Currency

29 apr. 2026, 06:03 UTC

Câștiguri

AstraZeneca 1Q Imfinzi Revenue $1.69B, Up 30% at Constant Currency

29 apr. 2026, 06:03 UTC

Câștiguri

AstraZeneca 1Q Tagrisso Revenue $1.83B, Up 5% at Constant Currency

29 apr. 2026, 06:02 UTC

Câștiguri

Analysts Saw AstraZeneca 1Q Core EPS at $2.54

29 apr. 2026, 06:01 UTC

Câștiguri

Analysts Saw AstraZeneca 1Q Revenue at $14.94B

29 apr. 2026, 06:01 UTC

Câștiguri

AstraZeneca Backs 2026 View

29 apr. 2026, 06:00 UTC

Câștiguri

AstraZeneca PLC 1Q Adj EPS $2.58

29 apr. 2026, 06:00 UTC

Câștiguri

AstraZeneca PLC 1Q Rev $15.29B

29 apr. 2026, 06:00 UTC

Câștiguri

AstraZeneca PLC 1Q Pretax Pft $3.91B

29 apr. 2026, 06:00 UTC

Câștiguri

AstraZeneca PLC 1Q Oper Pft $4.25B

29 apr. 2026, 06:00 UTC

Câștiguri

AstraZeneca PLC 1Q Net Pft $3.08B

29 apr. 2026, 06:00 UTC

Câștiguri

AstraZeneca PLC 1Q EPS $1.97

27 apr. 2026, 10:48 UTC

Market Talk

AstraZeneca Likely Unaffected by Partner Daiichi Sankyo's Supply Review -- Market Talk

10 apr. 2026, 11:57 UTC

Market Talk

AstraZeneca Likely to Increase Spending to Prepare for New Launches -- Market Talk

10 apr. 2026, 10:26 UTC

Market Talk
Câștiguri

AstraZeneca Expected to Reiterate Full-Year Guidance -- Market Talk

2 apr. 2026, 09:16 UTC

Market Talk

AstraZeneca Liver Cancer Trial Could Help Imfinzi Peak Sales Beat Views -- Market Talk

27 mar. 2026, 10:40 UTC

Market Talk

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

27 mar. 2026, 10:17 UTC

Market Talk

AstraZeneca Lung Disease Trial Adds Building Block to 2030 Target -- Market Talk

Comparație

Modificare preț

AstraZeneca PLC Așteptări

Obiectiv de preț

By TipRanks

17.01% sus

Prognoză pe 12 luni

Medie 16,076.92 GBX  17.01%

Maxim 18,600 GBX

Minim 11,300 GBX

În baza a 15 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAstraZeneca PLC - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

15 ratings

13

Cumpărare

1

Păstrare

1

Vânzare

Sentiment

By Acuity

53 / 345 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
help-icon Live chat